For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Synlogic Operating Company, Inc.

USPTO Granted Patents = 24

% Expired Patents = 4.2

EPO Patents = 6

Forward Citations = 54

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Vincent M Isabella (21 out of 25 patents)

Dean Falb (19 out of 23 patents)

Jonathan W Kotula (19 out of 25 patents)

4. Paul F Miller (19 out of 23 patents)

5. Yves Millet (15 out of 17 patents)

6. Adam B Fisher (10 out of 11 patents)

7. Sarah Rowe (8 out of 9 patents)

8. Suman Machinani (6 out of 8 patents)

9. Saurabh Saha (2 out of 39 patents)

10. Ning Li (2 out of 2 patents)

11. Adam Lawrence (2 out of 2 patents)

12. Per Greisen (2 out of 2 patents)

13. Kristin Adolfsen (2 out of 2 patents)

14. James Spoonamore (2 out of 2 patents)

15. Jay Konieczka (2 out of 2 patents)

24 patents: Sort by Forward Citations

1. 12721882 - Enumeration of genetically engineered microorganisms by live cell counting techniques (2026-09-01),

2. 12703866 - ENGINEERED MICROORGANISMS (2026-08-11),

3. 12545886 - BACTERIA FOR THE TREATMENT OF DISORDERS (2026-02-10),

4. 12409195 - Bacteria engineered to reduce hyperphenylalaninemia (2025-09-09),

5. 12171790 - Microorganisms engineered to reduce hyperphenylalaninemia (2024-12-24),

6. 11896627 - Bacteria engineered to treat metabolic diseases (2024-02-13),

7. 11883439 - Bacteria engineered to treat a disease or disorder (2024-01-30),

8. 11879123 - Bacteria for the treatment of disorders (2024-01-23),

9. 11859189 - Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof (2024-01-02),

10. 11845964 - Bacteria engineered to treat diseases associated with hyperammonemia (2023-12-19),

11. 11766463 - Microorganisms engineered to reduce hyperphenylalaninemia (2023-09-26),

12. 11723932 - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells (2023-08-15),

13. 11685925 - Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier (2023-06-27),

14. 11618894 - Bacteria engineered to reduce hyperphenylalaninemia (2023-04-04),

15. 11471494 - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells (2022-10-18),

Company Overview

Synlogic Operating Company, Inc. is a biotechnology firm based in Cambridge, MA, specializing in the development of synthetic biotics to treat various diseases. The company focuses on engineering living medicines that can address metabolic and genetic disorders by harnessing the power of microbiome-based therapies. With a commitment to innovative research, Synlogic aims to transform the treatment landscape for patients with unmet medical needs through its advanced platform technology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

24 Patents

#114 in Cambridge, MA

#829 in Massachusetts

#13,872 in US

#26,628 in the World

Cambridge, MA, United States of America

Synlogic Operating Company, Inc.

Forward Citations = 54

32 inventors:

Vincent M Isabella (21 out of 25 patents)

Dean Falb (19 out of 23 patents)

Jonathan W Kotula (19 out of 25 patents)

4. Paul F Miller (19 out of 23 patents)

5. Yves Millet (15 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Synlogic Operating Company, Inc.. Retrieved from https://idiyas.com/company/synlogic-operating-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…